[Telemedicine and fibrinolysis in Franche-Comté]

Rev Neurol (Paris). 2012 Jan;168(1):40-8. doi: 10.1016/j.neurol.2011.07.011. Epub 2011 Nov 21.
[Article in French]

Abstract

Introduction: The aim of our study was to compare the efficacy and safety of intravenous thrombolysis of cerebral ischemia as it has been established in a distant hospital (DH) through telemedicine tools or in neurovascular unit of the University Hospital of Besançon.

Method: Our work was conducted retrospectively at the University Hospital of Besançon from 1 January 2003 to December 31, 2009.

Results: Fibrinolysis was introduced at the university hospital in 98/161 patients (61%) and a DH in remote 63/161 patients (39%). A favorable neurological outcome (Rankin 0/1) was observed in 27/98 patients (27.5%) treated at University Hospital and in 25/63 (39.5%) patients in a DH. There was no significant difference between the two subgroups. Symptomatic hemorrhagic transformation occurred in 5/98 (5%) patients treated at University Hospital and in 1/63 (1.5%) patients treated in DH. There was no significant difference between the two subgroups.

Conclusion: Our study shows that fibrinolysis remotely using the tools of telemedicine has, from 2003 to 2009, in Franche-Comté deal effectively and without risk of a significant proportion of patients.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Aged, 80 and over
  • Brain Ischemia / drug therapy
  • Brain Ischemia / epidemiology
  • Cerebral Hemorrhage / epidemiology
  • Cerebral Hemorrhage / etiology
  • Female
  • Fibrinolytic Agents / therapeutic use
  • France / epidemiology
  • Hospitals, University
  • Humans
  • Male
  • Middle Aged
  • Nervous System Diseases / etiology
  • Nervous System Diseases / therapy
  • Patient Safety
  • Patient Transfer
  • Retrospective Studies
  • Stroke / drug therapy
  • Telemedicine / methods*
  • Thrombolytic Therapy / adverse effects
  • Thrombolytic Therapy / methods*
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator